Search

Your search keyword '"Santini D."' showing total 2,987 results
Start Over Author "Santini D."
2,987 results on '"Santini D."'

2. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

Author

Altavilla, Amelia, Atzori, Francesco, Banna, Giuseppe Luigi, Barni, Sandro, Basso, Umberto, Bauckneht, Matteo, Berardi, Rossana, Berruti, Alfredo, Bertoldo, Francesco, Bimbatti, Davide, Boccardo, Francesco, Buti, Sebastiano, Buttigliero, Consuelo, Caffo, Orazio, Calabrò, Fabio, Cattrini, Carlo, Cellini, Francesco, Conteduca, Vincenza, Cursano, Maria Concetta, De Feo, Giulia, De Giorgi, Ugo, Di Lorenzo, Giuseppe, Di Maio, Massimo, Di Napoli, Marilena, Ermacora, Paola, Fornarini, Giuseppe, Fratino, Lucia, Fusco, Vittorio, Gernone, Angela, Ibrahim, Toni, Lanzetta, Gaetano, Malgeri, Andrea, Maruzzo, Marco, Masini, Cristina, Messina, Carlo, Mosca, Alessandra, Naglieri, Emanuele, Nolè, Franco, Ortega, Cinzia, Palermo, Andrea, Pantano, Francesco, Prati, Veronica, Procopio, Giuseppe, Rescigno, Pasquale, Roberto, Michela, Rossetti, Sabrina, Roviello, Giandomenico, Santini, Daniele, Stellato, Marco, Tambaro, Rosa, Toma, Ilaria, Tucci, Marcello, Valsecchi, Anna Amela, Verzoni, Elena, Zanardi, Elisa, Zucali, Paolo Andrea, Cursano, M.C., Valsecchi, A.A., Pantano, F., Di Maio, M., Procopio, G., Berruti, A., Bertoldo, F., Tucci, M., De Giorgi, U., and Santini, D.

Published
2024
Full Text
View/download PDF

4. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

Author

Trevisan, B., Pepe, F. F., Vallini, I., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Baldelli, A., Fontana, A., Gambaro, A. R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Sarti, S., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Sarobba, M. G., Schintu, M. G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M. R., Vici, P., Clivio, L., Torri, V., and Cazzaniga, M. E.

Published
2023
Full Text
View/download PDF

12. Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials

Author

Dell’Aquila, E., Rossini, D., Fulgenzi, C.A.M., Passardi, A., Tamburini, E., Vetere, G., Carullo, M., Citarella, F., Antoniotti, C., Zaniboni, A., Pietrantonio, F., Spagnoletti, A., Marmorino, F., Borelli, B., Allegrini, G., Lonardi, S., Nappo, F., Masi, G., Cremolini, C., and Santini, D.

Published
2022
Full Text
View/download PDF

16. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study

Author

Procopio, Giuseppe, Chiuri, Vincenzo, Mantini, Giovanna, Roberto Bordonaro, Roberto Maisano., Cinieri, Saverio, Rossetti, Sabrina, De Placido, Sabino, Airoldi, Mario, Galli, Luca, Gasparro, Donatello, Ludovico, Giuseppe Mario, Guglielmini, Pamela Francesca, Santini, Daniele, Naglieri, Emanuele, Fagnani, Daniele, Aglietta, Massimo, Livi, Lorenzo, Schips, Luigi, Passalacqua, Rodolfo, Fiore, Michele, D'Angelillo, Rolando Maria, Ceresoli, Giovanni Luca, Magrini, Stefano, Rondonotti, David, Mirone, Vincenzo, Ferriero, Maria Consiglia, Sciarra, Alessandro, Acquati, Mirko, Boccardo, Francesco, Scagliotti, Giorgio Vittorio, Mencoboni, Manlio, De Giorgi, Ugo, Micheletti, Gennaro, Lanzetta, Gaetano, Sartori, Donata, Carlini, Paolo, Soto Parra, Hector Josè, Battaglia, Michele, Uricchio, Francesco, Bernardo, Antonio, De Lisa, Antonello, Carrieri, Giuseppe, Ardizzoia, Antonio, Aieta, Michele, Pisconti, Salvatore, Marchetti, Paolo, Paiar, Fabiola, Procopio, G., Chiuri, V.E., Giordano, M., Alitto, A.R., Maisano, R., Bordonaro, R., Cinieri, S., Rossetti, S., De Placido, S., Airoldi, M., Galli, L., Gasparro, D., Ludovico, G.M., Guglielmini, P.F., Carella, C., Nova, P., Aglietta, M., Schips, L., Beccaglia, P., Sciarra, A., Livi, L., and Santini, D.

Published
2022
Full Text
View/download PDF

17. Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO

Author

Rossini, D., Boccaccino, A., Sbrana, A., Daniel, F., Borelli, B., Raimondi, A., Santini, D., Conca, V., Tomasello, G., Caponnetto, S., Marmorino, F., Zaniboni, A., Buonadonna, A., Masi, G., Lonardi, S., Pietrantonio, F., Falcone, A., Antonuzzo, A., and Cremolini, C.

Published
2021
Full Text
View/download PDF

18. The role of androgen response pathway in association with tumor biology and response to neoadjuvant Immune-Checkpoint Inhibitors (ICI) in Muscle-Invasive urothelial Bladder Carcinoma (MIBC)

Author

Tateo, V., primary, Gibb, E.A., additional, Mercinelli, C., additional, Raggi, D., additional, Cigliola, A., additional, Patanè, D.A., additional, Crupi, E., additional, Giannatempo, P., additional, Colecchia, M., additional, Moschini, M., additional, Avesani, G., additional, Briganti, A., additional, Montorsi, F., additional, Santini, D., additional, and Necchi, A., additional

Published
2024
Full Text
View/download PDF

19. Clinical Application of Bladder MRI and Vesical Imaging-Reporting And Data System

Author

Panebianco, V., primary, Briganti, A., additional, Boellaard, T.N., additional, Catto, J., additional, Compera, E., additional, Efstathiou, J., additional, Van Der Heijden, A.G., additional, Giannarini, G., additional, Girometti, R., additional, Mertens, L., additional, Takeuchi, M., additional, Muglia, V.F., additional, Narumi, Y., additional, Novara, G., additional, Pecoraro, M., additional, Roupret, M., additional, Sanguedolce, F., additional, Santini, D., additional, Shariat, S.F., additional, Simone, G., additional, Vargas, H.A., additional, Woo, S., additional, Barentsz, J.O., additional, and Witjes, J.A., additional

Published
2024
Full Text
View/download PDF

21. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies

Author

Russo, A., Incorvaia, L., Del Re, M., Malapelle, U., Capoluongo, E., Gristina, V., Castiglia, M., Danesi, R., Fassan, M., Giuffrè, G., Gori, S., Marchetti, A., Normanno, N., Pinto, C., Rossi, G., Santini, D., Sartore-Bianchi, A., Silvestris, N., Tagliaferri, P., Troncone, G., Cinieri, S., and Beretta, G.D.

Published
2021
Full Text
View/download PDF

22. Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study

Author

Borelli, B., Fontana, E., Giordano, M., Antoniotti, C., Lonardi, S., Bergamo, F., Pietrantonio, F., Morano, F., Tamburini, E., Boccaccino, A., Santini, D., Zucchelli, G., Pella, N., Maiello, E., Passardi, A., Zaniboni, A., Ugolini, C., Fontanini, G., Falcone, A., Nyamundanda, G., Sadanandam, A., and Cremolini, C.

Published
2021
Full Text
View/download PDF

24. Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?

Author

Annibali, O., Petrucci, M.T., Santini, D., Bongarzoni, V., Russano, M., Pisani, F., Venditti, O., Pantano, F., Rago, A., Siniscalchi, A., Cerchiara, E., Franceschini, L., De Rosa, L., Mariani, M., Andriani, S, Cudillo, L., Garcia, M., Cantonetti, M., Mohamed, S., Anaclerico, B., Caravita, T., Stocchi, F., Cimino, G., Gumenyuk, S., Vozella, F., and Avvisati, G.

Published
2021
Full Text
View/download PDF

25. Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System.

Author

Panebianco, V, Briganti, A., Boellaard, T.N., Catto, J., Comperat, E., Efstathiou, J., Heijden, A.G. van der, Giannarini, G., Girometti, R., Mertens, L., Takeuchi, M., Muglia, V.F., Narumi, Y., Novara, G., Pecoraro, M., Roupret, M., Sanguedolce, F., Santini, D., Shariat, S.F., Simone, G., Vargas, H.A., Woo, S., Barentsz, J., Witjes, J.A., Panebianco, V, Briganti, A., Boellaard, T.N., Catto, J., Comperat, E., Efstathiou, J., Heijden, A.G. van der, Giannarini, G., Girometti, R., Mertens, L., Takeuchi, M., Muglia, V.F., Narumi, Y., Novara, G., Pecoraro, M., Roupret, M., Sanguedolce, F., Santini, D., Shariat, S.F., Simone, G., Vargas, H.A., Woo, S., Barentsz, J., and Witjes, J.A.

Abstract

Item does not contain fulltext, Diagnostic work-up and risk stratification in patients with bladder cancer before and after treatment must be refined to optimize management and improve outcomes. MRI has been suggested as a non-invasive technique for bladder cancer staging and assessment of response to systemic therapy. The Vesical Imaging-Reporting And Data System (VI-RADS) was developed to standardize bladder MRI image acquisition, interpretation and reporting and enables accurate prediction of muscle-wall invasion of bladder cancer. MRI is available in many centres but is not yet recommended as a first-line test for bladder cancer owing to a lack of high-quality evidence. Consensus-based evidence on the use of MRI-VI-RADS for bladder cancer care is needed to serve as a benchmark for formulating guidelines and research agendas until further evidence from randomized trials becomes available., 01 april 2024

Published
2024

29. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Author

Cicchiello, F., Riva, F., Vallini, I., Mazza, M., Bonfadini, C., Bordin, E., Canicattì, M., Cappuccio, F., Collovà, E., De Angelis, C., Desorte, R., Donati, S., Drudi, G., Galanti, D., Mocerino, C., Orlando, L., Pellegrino, B., Pizzuti, L., Ridolfi, C., Rocca, A., Sarti, D., Spagnoletti, I., Tinari, N., Vandone, A., Vizzini, L., Cazzaniga, M.E., Pinotti, G., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Fiorentini, G., Fontana, A., Gambaro, A.R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Marchetti, P., Melegari, E., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Saracchini, S., Sarobba, M.G., Schintu, M.G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M.R., Vici, P., Clivio, L., and Torri, V.

Published
2019
Full Text
View/download PDF

31. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes

Author

Cortellini, A., Leonetti, A., Catino, A., Pizzutillo, P., Ricciuti, B., De Giglio, A., Chiari, R., Bordi, P., Santini, D., Giusti, R., De Tursi, M., Brocco, D., Zoratto, F., Rastelli, F., Citarella, F., Russano, M., Filetti, M., Marchetti, P., Berardi, R., Torniai, M., Cortinovis, D., Sala, E., Maggioni, C., Follador, A., Macerelli, M., Nigro, O., Tuzi, A., Iacono, D., Migliorino, M. R., Banna, G., Porzio, G., Cannita, K., Ferrara, M. G., Bria, E., Galetta, D., Ficorella, C., and Tiseo, M.

Published
2020
Full Text
View/download PDF

32. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

Author

Trevisan, B, Pepe, F, Vallini, I, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Baldelli, A, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Sarti, S, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Clivio, L, Torri, V, Cazzaniga, M, Trevisan B., Pepe F. F., Vallini I., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Baldelli A., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Sarti S., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Clivio L., Torri V., Cazzaniga M. E., Trevisan, B, Pepe, F, Vallini, I, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Baldelli, A, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Sarti, S, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Clivio, L, Torri, V, Cazzaniga, M, Trevisan B., Pepe F. F., Vallini I., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Baldelli A., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Sarti S., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Clivio L., Torri V., and Cazzaniga M. E.

Abstract

Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT’s activity in a real-life setting of elderly MBC patients. Data of patients ≥ 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75–98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3–4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.

Published
2023

33. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author

Di Lisa, F, Krasniqi, E, Pizzuti, L, Barba, M, Cannita, K, De Giorgi, U, Borella, F, Foglietta, J, Cariello, A, Ferro, A, Picardo, E, Mitidieri, M, Sini, V, Stani, S, Tonini, G, Santini, D, La Verde, N, Gambaro, A, Grassadonia, A, Tinari, N, Garrone, O, Sarobba, G, Livi, L, Meattini, I, D'Auria, G, Vergati, M, Gamucci, T, Pistelli, M, Berardi, R, Risi, E, Giotta, F, Lorusso, V, Rinaldi, L, Artale, S, Cazzaniga, M, Zustovich, F, Cappuzzo, F, Landi, L, Torrisi, R, Scagnoli, S, Botticelli, A, Michelotti, A, Fratini, B, Saltarelli, R, Paris, I, Muratore, M, Cassano, A, Gianni, L, Gaspari, V, Veltri, E, Zoratto, F, Fiorio, E, Fabbri, M, Mazzotta, M, Ruggeri, E, Pedersini, R, Valerio, M, Filomeno, L, Minelli, M, Scavina, P, Raffaele, M, Astone, A, De Vita, R, Pozzi, M, Riccardi, F, Greco, F, Moscetti, L, Giordano, M, Maugeri-Sacca, M, Zennaro, A, Botti, C, Pelle, F, Cappelli, S, Cavicchi, F, Vizza, E, Sanguineti, G, Tomao, F, Cortesi, E, Marchetti, P, Tomao, S, Speranza, I, Sperduti, I, Ciliberto, G, Vici, P, Di Lisa F. S., Krasniqi E., Pizzuti L., Barba M., Cannita K., De Giorgi U., Borella F., Foglietta J., Cariello A., Ferro A., Picardo E., Mitidieri M., Sini V., Stani S., Tonini G., Santini D., La Verde N., Gambaro A. R., Grassadonia A., Tinari N., Garrone O., Sarobba G., Livi L., Meattini I., D'Auria G., Vergati M., Gamucci T., Pistelli M., Berardi R., Risi E., Giotta F., Lorusso V., Rinaldi L., Artale S., Cazzaniga M. E., Zustovich F., Cappuzzo F., Landi L., Torrisi R., Scagnoli S., Botticelli A., Michelotti A., Fratini B., Saltarelli R., Paris I., Muratore M., Cassano A., Gianni L., Gaspari V., Veltri E. M., Zoratto F., Fiorio E., Fabbri M. A., Mazzotta M., Ruggeri E. M., Pedersini R., Valerio M. R., Filomeno L., Minelli M., Scavina P., Raffaele M., Astone A., De Vita R., Pozzi M., Riccardi F., Greco F., Moscetti L., Giordano M., Maugeri-Sacca M., Zennaro A., Botti C., Pelle F., Cappelli S., Cavicchi F., Vizza E., Sanguineti G., Tomao F., Cortesi E., Marchetti P., Tomao S., Speranza I., Sperduti I., Ciliberto G., Vici P., Di Lisa, F, Krasniqi, E, Pizzuti, L, Barba, M, Cannita, K, De Giorgi, U, Borella, F, Foglietta, J, Cariello, A, Ferro, A, Picardo, E, Mitidieri, M, Sini, V, Stani, S, Tonini, G, Santini, D, La Verde, N, Gambaro, A, Grassadonia, A, Tinari, N, Garrone, O, Sarobba, G, Livi, L, Meattini, I, D'Auria, G, Vergati, M, Gamucci, T, Pistelli, M, Berardi, R, Risi, E, Giotta, F, Lorusso, V, Rinaldi, L, Artale, S, Cazzaniga, M, Zustovich, F, Cappuzzo, F, Landi, L, Torrisi, R, Scagnoli, S, Botticelli, A, Michelotti, A, Fratini, B, Saltarelli, R, Paris, I, Muratore, M, Cassano, A, Gianni, L, Gaspari, V, Veltri, E, Zoratto, F, Fiorio, E, Fabbri, M, Mazzotta, M, Ruggeri, E, Pedersini, R, Valerio, M, Filomeno, L, Minelli, M, Scavina, P, Raffaele, M, Astone, A, De Vita, R, Pozzi, M, Riccardi, F, Greco, F, Moscetti, L, Giordano, M, Maugeri-Sacca, M, Zennaro, A, Botti, C, Pelle, F, Cappelli, S, Cavicchi, F, Vizza, E, Sanguineti, G, Tomao, F, Cortesi, E, Marchetti, P, Tomao, S, Speranza, I, Sperduti, I, Ciliberto, G, Vici, P, Di Lisa F. S., Krasniqi E., Pizzuti L., Barba M., Cannita K., De Giorgi U., Borella F., Foglietta J., Cariello A., Ferro A., Picardo E., Mitidieri M., Sini V., Stani S., Tonini G., Santini D., La Verde N., Gambaro A. R., Grassadonia A., Tinari N., Garrone O., Sarobba G., Livi L., Meattini I., D'Auria G., Vergati M., Gamucci T., Pistelli M., Berardi R., Risi E., Giotta F., Lorusso V., Rinaldi L., Artale S., Cazzaniga M. E., Zustovich F., Cappuzzo F., Landi L., Torrisi R., Scagnoli S., Botticelli A., Michelotti A., Fratini B., Saltarelli R., Paris I., Muratore M., Cassano A., Gianni L., Gaspari V., Veltri E. M., Zoratto F., Fiorio E., Fabbri M. A., Mazzotta M., Ruggeri E. M., Pedersini R., Valerio M. R., Filomeno L., Minelli M., Scavina P., Raffaele M., Astone A., De Vita R., Pozzi M., Riccardi F., Greco F., Moscetti L., Giordano M., Maugeri-Sacca M., Zennaro A., Botti C., Pelle F., Cappelli S., Cavicchi F., Vizza E., Sanguineti G., Tomao F., Cortesi E., Marchetti P., Tomao S., Speranza I., Sperduti I., Ciliberto G., and Vici P.

Abstract

Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available. Methods: We carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recruited. We primarily focused on treatment tolerability, with toxicity being reported as potential cause of treatment discontinuation. Secondarily, we assessed effectiveness in the overall study population and in a subset having a minimum follow-up of 2 years. Results: Overall, 270 patients were retrospectively identified. The 50.4% of the patients had residual node positive disease, 7.8% and 81.9% had large or G3 residual tumor, respectively, and 80.4% a Ki-67 >20%. Toxicity-related treatment discontinuation was observed only in 10.4% of the patients. In the whole population, at a median follow-up of 15 months, 2-year disease-free survival was 62%, 2 and 3-year overall survival 84.0% and 76.2%, respectively. In 129 patients with a median follow-up of 25 months, 2-year disease-free survival was 43.4%, 2 and 3-year overall survival 78.0% and 70.8%, respectively. Six or more cycles of capecitabine were associated with more favourable outcomes compared with less than six cycles. Conclusion: The CaRe study shows an unexpectedly good tolerance of adjuvant capecitabine in a real-world setting, although effectiveness appears to be lower than that observed in the CREATE-X study. Methodological differences between the two studies impose significant limits to comparability concerning ef

Published
2023

34. Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial

Author

Grünwald, V., primary, McKay, R.R., additional, Buchler, T., additional, Masatoshi, E., additional, Park, S.H., additional, Takagi, T., additional, Zanetta, S., additional, Keizman, D., additional, Suárez, C., additional, Négrier, S., additional, Lee, J.L., additional, Santini, D., additional, Bedke, J., additional, Staehler, M., additional, Kollmannsberger, C., additional, Choueiri, T., additional, Motzer, R., additional, Burgents, J., additional, Okpara, C., additional, and Powles, T., additional

Published
2023
Full Text
View/download PDF

35. 1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial

Author

Gruenwald, V., primary, McKay, R.R., additional, Buchler, T., additional, Eto, M., additional, Park, S.H., additional, Takagi, T., additional, Zanetta, S., additional, Keizman, D., additional, Rodriguez, C. Suarez, additional, Negrier, S., additional, Lee, J-L., additional, Santini, D., additional, Bedke, J., additional, Staehler, M., additional, Kollmannsberger, C.K., additional, Choueiri, T.K., additional, Motzer, R.J., additional, Burgents, J., additional, Okpara, C.E., additional, and Powles, T.B., additional

Published
2023
Full Text
View/download PDF

37. Bone metastases in biliary cancers: A multicenter retrospective survey

Author

Santini, D, Brandi, G, Aprile, G, Russano, M, Cereda, S, Leone, F, Lonardi, S, Fornaro, L, Scartozzi, M, Silvestris, N, Barni, S, Pantano, F, Vincenzi, B, Palloni, A, Frega, G, Casagrande, M, Ferrari, L, Dadduzio, V, Intini, R, Filippi, R, Vasile, E, Vivaldi, C, Faloppi, L, Brunetti, O, Reni, M, Aglietta, M, and Tonini, G

Published
2018
Full Text
View/download PDF

38. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Author

Dell’Aquila, E., Cremolini, C., Zeppola, T., Lonardi, S., Bergamo, F., Masi, G., Stellato, M., Marmorino, F., Schirripa, M., Urbano, F., Ronzoni, M., Tomasello, G., Zaniboni, A., Racca, P., Buonadonna, A., Allegrini, G., Fea, E., Di Donato, S., Chiara, S., Tonini, G., Tomcikova, D., Boni, L., Falcone, A., and Santini, D.

Published
2018
Full Text
View/download PDF

40. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

Author

Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, Martinelli, E, Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, and Martinelli, E

Subjects
metastatic colorectal cancer, cetuximab, rechallenge, immunotherapy
Abstract

The rechallenge strategy is based on the concept that a subset of patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti-EGFR based-therapy. We performed a pooled analysis of two-phase II prospective trials to determine the role of rechallenge in third-line mCRC patients with RAS/BRAF WT baseline circulating tumor DNA (ctDNA). Individual data of 33 and 13 patients from CAVE and CRICKET trials that received as third-line therapy cetuximab rechallenge were collected. Overall survival (OS), Progression-free survival (PFS), Overall response rate (ORR), Stable disease (SD) > 6 months were calculated. Adverse events were reported. For the whole 46 patient population, median PFS (mPFS) was 3.9 months (95% Confidence Interval, CI 3.0-4.9) with median OS (mOS) of 16.9 months (95% CI 11.7-22.1). For CRICKET patients, mPFS was 3.9 months (95% CI 1.7-6.2); mOS was 13.1 months (95% CI 7.3-18.9) with OS rates at 12, 18, and 24 months of 62%, 23%, and 0%, respectively. For CAVE patients, mPFS was 4.1 months (95% CI 3.0-5.2); mOS was 18.6 months (95% CI 11.7-25.4) with OS rates at 12, 18, 24 months of 61%, 52%, 21%, respectively. Skin rash was more frequently reported in CAVE trial (87.9% vs. 30.8%; p = 0.001), whereas a increased incidence of hematological toxicities was observed in CRICKET trial (53.8%% vs. 12.1%; p = 0.003). Third-line cetuximab rechallenge in combination with either irinotecan or avelumab in RAS/BRAF WT ctDNA mCRC patients represents a promising therapy.

Published
2023

41. 236P Trastuzumab deruxtecan in Italian real-world experience: Updated analysis from DE-REAL study

Author

Botticelli, A., primary, Pisegna, S., additional, Scagnoli, S., additional, Santini, D., additional, De Laurentiis, M., additional, Caputo, R., additional, Scafetta, R., additional, Palleschi, M., additional, Orlandi, A., additional, Ballatore, Z., additional, Giampaglia, M., additional, Chiavassa, A., additional, Alesini, D., additional, Rossi, L., additional, Fabbri, M.A., additional, D'Auria, G., additional, Vici, P., additional, Strigari, L., additional, Marchetti, P., additional, and Fabi, A., additional

Published
2023
Full Text
View/download PDF

42. 224P Clinical features and outcomes in HER2+ mBC patients treated with trastuzumab deruxtecan: A subgroup analysis of the De-REAL study

Author

Botticelli, A., primary, Scagnoli, S., additional, Pisegna, S., additional, Santini, D., additional, De Laurentiis, M., additional, Caputo, R., additional, Verrazzo, A., additional, Scafetta, R., additional, Orlandi, A., additional, Palleschi, M., additional, Alesini, D., additional, Barberi, V., additional, Fabbri, M.A., additional, D'Auria, G., additional, Strigari, L., additional, Ballatore, Z., additional, Tedesco, B., additional, Preissner, R., additional, Marchetti, P., additional, and Fabi, A., additional

Published
2023
Full Text
View/download PDF

43. Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials

Author

Martini, G., primary, Ciardiello, D., additional, Famiglietti, V., additional, Rossini, D., additional, Antoniotti, C., additional, Troiani, T., additional, Napolitano, S., additional, Esposito, L., additional, Latiano, T. P., additional, Maiello, E., additional, Del Re, M., additional, Lonardi, S., additional, Aprile, G., additional, Santini, D., additional, Masi, G., additional, Avallone, A., additional, Normanno, N., additional, Pietrantonio, F., additional, Pinto, C., additional, Ciardiello, F., additional, Cremolini, C., additional, and Martinelli, E., additional

Published
2023
Full Text
View/download PDF

44. OC.15.2 SMALL BOWEL CARCINOMAS MAY COMPLICATE COELIAC DISEASE DESPITE STRICT ADHERENCE TO GLUTEN-FREE DIET: A CASE SERIES FROM THE SMALL BOWEL CANCER ITALIAN CONSORTIUM

Author

Bianchi, P.I., primary, Vanoli, A., additional, Lenti, M., additional, Guerini, C., additional, Arpa, G., additional, Quaquarini, E., additional, Aronico, N., additional, Grillo, F., additional, Nesi, G., additional, Furlan, D., additional, Latella, G., additional, Sessa, F., additional, Mescoli, C., additional, Rugge, M., additional, Ferrero, S., additional, Macciomei, M., additional, Santini, D., additional, Volta, U., additional, De Giorgio, R., additional, Caio, G., additional, Calabro, A., additional, Ciacci, C., additional, D'Armiento, M., additional, Villanacci, V., additional, Cannizzaro, R., additional, Canzonieri, V., additional, Florena, A., additional, Ciardi, A., additional, Elli, L., additional, Vecchi, M., additional, Zingone, F., additional, Reggiani Bonetti, L., additional, Astegiano, M., additional, Sandri, G., additional, Silano, M., additional, Usai, P., additional, Perfetti, V., additional, Giannone, A., additional, Barresi, V., additional, Ciccocioppo, R., additional, Biletta, E., additional, Corazza, G., additional, and Di Sabatino, A., additional

Published
2023
Full Text
View/download PDF

45. PC.01.9 HYPOMETHYLATION OF LINE-1 IN SMALL BOWEL CARCINOMAS AND COELIAC DISEASE

Author

Guerini, C., primary, Bianchi, P.I., additional, Libera, L., additional, Vanoli, A., additional, Arpa, G., additional, Aronico, N., additional, Furlan, D., additional, Grillo, F., additional, Nesi, G., additional, Sampietro, G., additional, Ardizzone, S., additional, Fociani, P., additional, Fiocca, R., additional, Latella, G., additional, Sessa, F., additional, D'Errico, A., additional, Malvi, D., additional, Mescoli, C., additional, Rugge, M., additional, Ferrero, S., additional, Poggioli, G., additional, Rizzello, F., additional, Macciomei, M., additional, Santini, D., additional, Volta, U., additional, De Giorgio, R., additional, Caio, G., additional, Calabro, A., additional, Ciacci, C., additional, D'Armiento, M., additional, Rizzo, A., additional, Solina, G., additional, Tonelli, F., additional, Villanacci, V., additional, Cannizzaro, R., additional, Canzonieri, V., additional, Florena, A., additional, Biancone, L., additional, Monteleone, G., additional, Caronna, R., additional, Ciardi, A., additional, Elli, L., additional, Caprioli, F., additional, Vecchi, M., additional, D'Inca, R., additional, Zingone, F., additional, D'Odorico, A., additional, Oreggia, B., additional, Reggiani Bonetti, L., additional, Astegiano, M., additional, Cantoro, L., additional, Papi, C., additional, Sandri, G., additional, Silano, M., additional, Usai, P., additional, Perfetti, V., additional, Quaquarini, E., additional, Giannone, A., additional, Orlandi, A., additional, Barresi, V., additional, Ciccocioppo, R., additional, Amodeo, G., additional, Biletta, E., additional, and Di Sabatino, A., additional

Published
2023
Full Text
View/download PDF

46. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience

Author

Moscetti, L., Vici, P., Gamucci, T., Natoli, C., Cortesi, E., Marchetti, P., Santini, D., Giuliani, R., Sperduti, I., Mauri, M., Pizzuti, L., Mancini, M.L., Fabbri, M.A., Magri, V., Iezzi, L., Sini, V., D'Onofrio, L., Mentuccia, L., Vaccaro, A., Ramponi, S., Roma, C.L., and Ruggeri, E.M.

Published
2016
Full Text
View/download PDF

47. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

Author

Hadji, P., Coleman, R.E., Wilson, C., Powles, T.J., Clézardin, P., Aapro, M., Costa, L., Body, J.-J., Markopoulos, C., Santini, D., Diel, I., Di Leo, A., Cameron, D., Dodwell, D., Smith, I., Gnant, M., Gray, R., Harbeck, N., Thurlimann, B., Untch, M., Cortes, J., Martin, M., Albert, U.-S., Conte, P.-F., Ejlertsen, B., Bergh, J., Kaufmann, M., and Holen, I.

Published
2016
Full Text
View/download PDF

48. Radiologically defined lipid-poor adrenal adenomas: histopathological characteristics

Author

De Leo, A., Mosconi, C., Zavatta, G., Tucci, L., Nanni, C., Selva, S., Balacchi, C., Ceccarelli, C., Santini, D., Pantaleo, M. A., Minni, F., Fanti, S., Golfieri, R., Pagotto, U., Vicennati, V., and Di Dalmazi, G.

Abstract

Background: Adrenal lipid-poor adenomas (LPA) are defined by high unenhanced density (≥ 10 HU), and absolute and relative contrast medium washout > 60% and > 40%, respectively, at computerized tomography (CT). To date, no thorough histopathological characterization has been performed in those frequent lesions (one-third of adrenal adenomas). Our aim was to analyze the histopathological characteristics of adrenal LPA. Methods: Patients with LPA (n= 57) were selected among consecutive subjects referred for an adrenal incidentaloma or ACTH-independent Cushing syndrome. FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) was performed in 37 patients. In patients treated by adrenalectomy (n= 17), Weiss score and Lin–Weiss–Bisceglia score (in tumors composed entirely or predominantly of oncocytes) were calculated. Results: Radiological parameters did not differ among patients with ACTH-independent Cushing syndrome (n= 6) and those with adrenal incidentalomas associated with primary aldosteronism (n= 2), autonomous cortisol secretion (n= 14), or non-functioning (n= 35). Patients treated by adrenalectomy had larger tumors (28.9 ± 11.2 vs17.3 ± 8.4 mm,P< 0.001), higher CT unenhanced density (29.1 ± 11.0 vs23.1 ± 9.0 HU, P= 0.043), and FDG-PET adrenal uptake (9.0 ± 6.4 vs4.4 ± 2.3 SUV, P= 0.003) than non-operated ones. Oncocytic features > 75% of the tumor were detected in 12/17 cases (70.6%). Five of those showed borderline-malignant histopathological characteristics by Lin–Weiss–Bisceglia score. Among remaining non-oncocytic tumors, 1/5 had a Weiss score ≥ 3. Overall, 6/17 tumors (35.3%) had borderline-malignant potential. Radiological parameters were similar between patients with benign and borderline-malignant tumors. Conclusions: Adrenal LPA are a heterogeneous group of tumors, mostly composed of oncocytomas. Up to 1/3 of those tumors may have a borderline-malignant potential at histopathology.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results